Overview

Abatacept as GVHD Prophylaxis Phase 2

Status:
Active, not recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections.

Phase:

Phase 2

Details

Lead Sponsor:

Boston Children's Hospital
Seattle Children's Hospital

Collaborator:

FDA Office of Orphan Products Development

Treatments:

Abatacept
Calcineurin Inhibitors
Methotrexate